|
|
|
|
|||||
|
|
|
Yupelri's strength helped Theravance achieve non-GAAP profitability this quarter.
The company is on track for lucrative milestones.
The results of a phase 3 trial are expected in early 2026.
Shares in Theravance Biopharma (NASDAQ: TBPH) surged by more than 21% as of noontime ET today. The move comes as the market digests the previous day's excellent third-quarter results and corporate update.
The pharmaceutical company is making good progress on its plans, specifically to develop sales of its once-daily nebulized (a drug delivery device that administers mist into lungs) long-acting muscarinic agent (LAMA), Yupelri (revefenacin), and generate earnings and cash flow from it, while advancing another key drug through phase 3.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
The latter is ampreloxetine, described by the company as "an investigational, once-daily, selective norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy."
There was good news on both. Yupelri (which is marketed by Viatris) beat sales expectations in the quarter with record sales of $71.4 million. As management noted, it only needs $54 million in the fourth quarter to trigger a milestone payment (from Viatris) of $25 million for hitting $250 million in sales in 2025.
Theravance is also on track to receive a $50 million milestone from Royalty Pharma (which paid Theravance for royalty rights) on GSK's sales of chronic obstructive pulmonary disease (COPD) and asthma medication, Trelegy, in 2025 and possibly a $100 million payment in 2026, too.
Image source: Getty Images.
Yupelri helped the company achieve non-GAAP (generally accepted accounting principles) profitability. With enrollment complete in the phase 3 trial for ampreloxetine (top-line results expected in the first quarter of 2026) , there's a lot to look forward to for Theravance investors.
Before you buy stock in Theravance Biopharma, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Theravance Biopharma wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $604,044!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,220,149!*
Now, it’s worth noting Stock Advisor’s total average return is 1,064% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of November 10, 2025
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends GSK. The Motley Fool has a disclosure policy.
| 2 hours | |
| 6 hours | |
| 16 hours | |
| Nov-10 | |
| Nov-10 | |
| Nov-10 | |
| Nov-06 | |
| Oct-30 | |
| Oct-29 | |
| Oct-27 | |
| Oct-16 | |
| Oct-14 | |
| Sep-11 | |
| Sep-02 | |
| Aug-25 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite